| # | Drug | Count |
|---|---|---|
| 0 | LAMIVUDINE | 145 |
| 1 | ENTECAVIR | 144 |
| 2 | LAMIVUDINE ORAL | 139 |
| 3 | TENOFOVIR DISOPROXIL FUMARATE | 128 |
| 4 | ENTECAVIR ANHYDROUS | 87 |
| 5 | TENOFOVIR DISOPROXIL FUMARATE TABLETS | 53 |
| 6 | ADEFOVIR DIPIVOXIL | 36 |
| 7 | TENOFOVIR ALAFENAMIDE | 35 |
| 8 | PREDNISOLONE | 33 |
| 9 | PREDNISOLONE ORAL | 33 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ADEFOVIR DIPIVOXIL | 36 | 0.0283 |
| 1 | ENTECAVIR | 144 | 0.0122 |
| 2 | BULEVIRTIDE | 1 | 0.0104 |
| 3 | TENOFOVIR DISOPROXIL FUMARATE TABLETS | 53 | 0.0061 |
| 4 | LAMIVUDINE | 145 | 0.0057 |
| 5 | RALTEGRAVIR | 17 | 0.0032 |
| 6 | CABOTEGRAVIR SODIUM | 4 | 0.0025 |
| 7 | MARAVIROC | 5 | 0.0022 |
| 8 | BARICITINIB | 5 | 0.0016 |
| 9 | DARUNAVIR 600 MG | 10 | 0.0016 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 207 | 0.0042 |
| 1 | CCR5 Co-receptor Antagonist [EPC] | 5 | 0.0022 |
| 2 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 196 | 0.0018 |
| 3 | Protease Inhibitor [EPC] | 24 | 0.0005 |
| 4 | Cytochrome P450 3A Inhibitor [EPC] | 26 | 0.0004 |
| 5 | Cytomegalovirus pUL97 Kinase Inhibitor [EPC] | 1 | 0.0004 |
| 6 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 8 | 0.0003 |
| 7 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] | 17 | 0.0003 |
| 8 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 4 | 0.0003 |
| 9 | Hepatitis C Virus NS5A Inhibitor [EPC] | 9 | 0.0002 |